Substance
TREPROSTINIL
Global reference: every product and company linked to this substance.
- cas: 81846-19-7
- ncit: C61983
- pubchem_cid: 6918140
- rxnorm: 343048
- unii: RUM6K67ESG
15-AU-81 · 15AU81 · L-606 · L606 · LRX-15 · REMODULIN · RUMODOLIN · treprostinil [INN] · TREPROSTINIL [JAN] · TREPROSTINIL [USAN] · Treprostinil [WHO-DD] · TYVASO
Revenue by product (3)
| Company | Product | Latest period | Revenue |
|---|---|---|---|
| UNITED THERAPEUTICS CORPORATION COMMON STOCK | TYVASO DPI | Q2 2026 | $326.6M |
| UNITED THERAPEUTICS CORPORATION COMMON STOCK | REMODULIN | Q2 2026 | $126.3M |
| UNITED THERAPEUTICS CORPORATION COMMON STOCK | TYVASO | Q2 2026 | $126.0M |
A figure belongs to the product it was reported for. It is never summed across companies or across a company's products, so one substance in three products shows three figures.
Products containing this substance (4)
- REMODULIN · UNITED THERAPEUTICS CORPORATION COMMON STOCK
- TREPROSTINIL · DR. REDDY'S LABORATORIES LTD COMMON STOCK
- TYVASO · UNITED THERAPEUTICS CORPORATION COMMON STOCK
- TYVASO DPI · UNITED THERAPEUTICS CORPORATION COMMON STOCK